4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.

A replay webcast of the presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com for 90 days following the presentation.

About 4D pharma

4d pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4d pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients with Parkinson’s disease is expected to commence in 2022. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer. The Company has a research collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics for vaccines.

4D Investor Relations ir@4dpharmaplc.com

Singer Capital Markets - Nominated Adviser and Joint Broker Philip Davies / James Fischer (Corporate Finance) +44 (0)20 7496 3000

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker Dominic Wilson +44 (0)20 7332 2500

Stern Investor Relations Julie Seidel +1-212-362-1200 julie.seidel@sternir.com

Image Box Communications Neil Hunter / Michelle Boxall +44 (0)20 8943 4685 neil@ibcomms.agency / michelle@ibcomms.agency

4d Pharma (LSE:DDDD)
Historical Stock Chart
From Nov 2023 to Dec 2023 Click Here for more 4d Pharma Charts.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Dec 2022 to Dec 2023 Click Here for more 4d Pharma Charts.